X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Glenmark Pharma with ALEMBIC PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs ALEMBIC PHARMA - Comparison Results

GLENMARK PHARMA    Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA ALEMBIC PHARMA GLENMARK PHARMA/
ALEMBIC PHARMA
 
P/E (TTM) x 15.4 15.9 97.4% View Chart
P/BV x 2.8 3.5 80.0% View Chart
Dividend Yield % 0.4 1.1 34.4%  

Financials

 GLENMARK PHARMA   ALEMBIC PHARMA
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-18
ALEMBIC PHARMA
Mar-19
GLENMARK PHARMA/
ALEMBIC PHARMA
5-Yr Chart
Click to enlarge
High Rs930664 140.1%   
Low Rs517412 125.5%   
Sales per share (Unadj.) Rs322.6208.7 154.6%  
Earnings per share (Unadj.) Rs28.531.0 91.9%  
Cash flow per share (Unadj.) Rs39.237.1 105.6%  
Dividends per share (Unadj.) Rs2.005.50 36.4%  
Dividend yield (eoy) %0.31.0 27.0%  
Book value per share (Unadj.) Rs183.0144.2 126.9%  
Shares outstanding (eoy) m282.17188.52 149.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.22.6 87.0%   
Avg P/E ratio x25.417.4 146.3%  
P/CF ratio (eoy) x18.514.5 127.3%  
Price / Book Value ratio x4.03.7 106.0%  
Dividend payout %7.017.7 39.6%   
Avg Mkt Cap Rs m204,206101,461 201.3%   
No. of employees `00013.7NA-   
Total wages/salary Rs m18,7187,467 250.7%   
Avg. sales/employee Rs Th6,636.8NM-  
Avg. wages/employee Rs Th1,364.7NM-  
Avg. net profit/employee Rs Th586.1NM-  
INCOME DATA
Net Sales Rs m91,03139,347 231.4%  
Other income Rs m91494 974.4%   
Total revenues Rs m91,94539,441 233.1%   
Gross profit Rs m16,1548,736 184.9%  
Depreciation Rs m3,0191,152 262.0%   
Interest Rs m2,856184 1,551.2%   
Profit before tax Rs m11,1937,493 149.4%   
Minority Interest Rs m011 0.0%   
Prior Period Items Rs m0-93 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,1551,568 201.3%   
Profit after tax Rs m8,0395,844 137.6%  
Gross profit margin %17.722.2 79.9%  
Effective tax rate %28.220.9 134.7%   
Net profit margin %8.814.9 59.5%  
BALANCE SHEET DATA
Current assets Rs m69,88719,577 357.0%   
Current liabilities Rs m32,87914,896 220.7%   
Net working cap to sales %40.711.9 341.7%  
Current ratio x2.11.3 161.7%  
Inventory Days Days8190 90.7%  
Debtors Days Days9345 206.2%  
Net fixed assets Rs m28,89227,097 106.6%   
Share capital Rs m282377 74.9%   
"Free" reserves Rs m51,35326,811 191.5%   
Net worth Rs m51,63527,188 189.9%   
Long term debt Rs m41,4184,993 829.5%   
Total assets Rs m125,95447,778 263.6%  
Interest coverage x4.941.7 11.8%   
Debt to equity ratio x0.80.2 436.8%  
Sales to assets ratio x0.70.8 87.8%   
Return on assets %8.612.6 68.6%  
Return on equity %15.621.5 72.4%  
Return on capital %15.123.6 64.0%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m36,31719,453 186.7%   
Fx outflow Rs m9,7206,065 160.3%   
Net fx Rs m26,59813,388 198.7%   
CASH FLOW
From Operations Rs m16,4818,120 203.0%  
From Investments Rs m-10,133-7,556 134.1%  
From Financial Activity Rs m-4,685590 -793.5%  
Net Cashflow Rs m1,7701,153 153.5%  

Share Holding

Indian Promoters % 48.3 74.1 65.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 6.9 2.9 237.9%  
FIIs % 34.4 9.1 378.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 13.9 75.5%  
Shareholders   56,727 49,328 115.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   VENUS REMEDIES  SHASUN PHARMA  PFIZER  TTK HEALTHCARE  ORCHID PHARMA LTD  

Compare GLENMARK PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Jet Airways and Yes Bank - What's Next for these Beaten Down Stocks?(Podcast)

Jet Airways and Yes Bank, both once market darlings are now being shunned by market participants. The National Stock Exchange (NSE) exchange notified that the shares of the airline.

Related Views on News

ALEMBIC PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 13, 2019 | Updated on Jun 13, 2019

Here's an analysis of the annual report of ALEMBIC PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of ALEMBIC PHARMA. Also includes updates on the valuation of ALEMBIC PHARMA.

GLENMARK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 6.6% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 6.6% YoY). Sales on the other hand came in at Rs 26 bn (up 12.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 28.9% (Quarterly Result Update)

May 9, 2019 | Updated on May 9, 2019

For the quarter ended March 2019, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 28.9% YoY). Sales on the other hand came in at Rs 9 bn (up 8.6% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 11.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, GLENMARK PHARMA has posted a net profit of Rs 1 bn (up 11.1% YoY). Sales on the other hand came in at Rs 26 bn (up 15.9% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

ALEMBIC PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 21, 2018 | Updated on Dec 21, 2018

Here's an analysis of the annual report of ALEMBIC PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ALEMBIC PHARMA. Also includes updates on the valuation of ALEMBIC PHARMA.

More Views on News

Most Popular

The Best 4 Small-cap Stocks to Buy(The 5 Minute Wrapup)

Jun 3, 2019

In the sometimes good sometimes bad market of small caps, there are strong buying opportunities available today. But this great opportunity won't last forever.

The Great Indian NBFC Bubble Has Burst but I Will Still Recommend These Safe NBFCs(The 5 Minute Wrapup)

Jun 11, 2019

One chart that predicted the NBFC crisis back in 2016.

7 Stocks That Will Remain Evergreen in this Era of Technological Disruption(The 5 Minute Wrapup)

Jun 13, 2019

We are living in an era of disruption. Are your stocks well equipped to adapt to changes that disruption will bring along?

The Top 7 Stocks to Profit from Modi's Repeat Performance(Profit Hunter)

Jun 3, 2019

The long-term India story looks promising with the Modi government back in power. Which stocks are likely to go up the most?

Just One Stock Made Buffett Billions - And Can Make You Crores(Profit Hunter)

Jun 6, 2019

Coca Cola is arguably one of Warren Buffet's best stock picks. But did you know that small investors picked up the stock five decades before Buffet? Read on...

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Jun 14, 2019 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA - PFIZER COMPARISON

COMPARE GLENMARK PHARMA WITH

MARKET STATS